Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for NATCOPHARM
Revenue projections for NATCOPHARM

Investors may react cautiously to news that NATCOPHARM's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 27.816793
debtToEquity 3.012000
earningsGrowth 0.139000
revenueGrowth 0.363000
grossMargins 0.819710
operatingMargins 0.173800
trailingEps 86.910000
forwardEps 39.300000

NATCOPHARM's Forward PE ratio suggests the stock price is reasonable in relation to earnings. It's not overpriced, providing room for future growth, making the stock a potentially valuable investment for those seeking long-term gains.
With both earnings and revenue growth showing positive trends, NATCO Pharma Limited is expected to expand its business. This signals a healthy financial trajectory, suggesting that the company is positioned for continued growth and increasing profitability.
NATCOPHARM's forward EPS being lower than its trailing EPS suggests that the company is expected to see a decline in profitability. This signals that the company may face a challenging financial year ahead.

Price projections:

Price projections for NATCOPHARM
Price projections for NATCOPHARM

The price of NATCOPHARM has often been situated close to the lower end of projections. This consistent trend may signal difficulties for the company in achieving investor expectations for future performance.

Insider Transactions:

Insider Transactions for NATCOPHARM
Insider Transactions for NATCOPHARM


Recent trading of NATCOPHARM stock saw 6 sales, with market price at 893.3249918619791 per share.NATCOPHARM stock was bought in 2 transactions, while the market price was at 851.625.The insider transaction records show no compelling upward or downward trend, providing little insight into the company’s potential direction.

Recommendation changes over time:

Recommendations trend for NATCOPHARM
Recommendations trend for NATCOPHARM


Analysts have shown a buy bias for NATCOPHARM, marking it as a favorable investment option. This could inspire investors to see NATCOPHARM as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.